Metformin Induces Lipogenesis and Apoptosis in H4IIE Hepatocellular Carcinoma Cells
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Metformin is the most widely used anti-diabetic drug that helps maintain normal blood glucose levels primarily by suppressing hepatic gluconeogenesis in type II diabetic patients. We previously found that metformin induces apoptotic death in H4IIE rat hepatocellular carcinoma cells. Despite its anti-diabetic roles, the effect of metformin on hepatic de novo lipogenesis (DNL) remains unclear. We investigated the effect of metformin on hepatic DNL and apoptotic cell death in H4IIE cells. Metformin treatment stimulated glucose consumption, lactate production, intracellular fat accumulation, and the expressions of lipogenic proteins. It also stimulated apoptosis but reduced autophagic responses. These metformin-induced changes were clearly reversed by compound C, an inhibitor of AMP-activated protein kinase (AMPK). Interestingly, metformin massively increased the production of reactive oxygen species (ROS), which was completely blocked by compound C. Metformin also stimulated the phosphorylation of p38 mitogen-activated protein kinase (p38MAPK). Finally, inhibition of p38MAPK mimicked the effects of compound C, and suppressed the metformininduced fat accumulation and apoptosis. Taken together, metformin stimulates dysregulated glucose metabolism, intracellular fat accumulation, and apoptosis. Our findings suggest that metformin induces excessive glucose-induced DNL, oxidative stress by ROS generation, activation of AMPK and p38MAPK, suppression of autophagy, and ultimately apoptosis.
Abstract
Metformin is the most widely used anti-diabetic drug that helps maintain normal blood glucose levels primarily by suppressing hepatic gluconeogenesis in type II diabetic patients. We previously found that metformin induces apoptotic death in H4IIE rat hepatocellular carcinoma cells. Despite its anti-diabetic roles, the effect of metformin on hepatic de novo lipogenesis (DNL) remains unclear. We investigated the effect of metformin on hepatic DNL and apoptotic cell death in H4IIE cells. Metformin treatment stimulated glucose consumption, lactate production, intracellular fat accumulation, and the expressions of lipogenic proteins. It also stimulated apoptosis but reduced autophagic responses. These metformin-induced changes were clearly reversed by compound C, an inhibitor of AMP-activated protein kinase (AMPK). Interestingly, metformin massively increased the production of reactive oxygen species (ROS), which was completely blocked by compound C. Metformin also stimulated the phosphorylation of p38 mitogen-activated protein kinase (p38MAPK). Finally, inhibition of p38MAPK mimicked the effects of compound C, and suppressed the metformininduced fat accumulation and apoptosis. Taken together, metformin stimulates dysregulated glucose metabolism, intracellular fat accumulation, and apoptosis. Our findings suggest that metformin induces excessive glucose-induced DNL, oxidative stress by ROS generation, activation of AMPK and p38MAPK, suppression of autophagy, and ultimately apoptosis.
참고문헌 (38)
- Barzilai N, "Metformin as a tool to target aging", Cell Metab, 23, pp.1060~1065 (2016)
- Bhalla K, "Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis", Cancer Prev Res, 5, pp.544~552 (2012)
- Bray F, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA: A Cancer J Clin, 68, pp.394~424 (2018)
- Das S, "Mechanism of interaction between autophagy and apoptosis in cancer", Apoptosis, 26, pp.512~533 (2021)
- DePeralta DK, "Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis", Cancer, 122, pp.1216~1227 (2016)
- DeWaal D, "Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin", Nat Commun, 9, pp.446~ (2018)
- Forslund K, "Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota", Nature, 528, pp.262~266 (2015)
- Halliwell B, "Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean?", Br J Pharmacol, 142, pp.231~255 (2004)
- Han Y, "Post-translational regulation of lipogenesis via AMPKdependent phosphorylation of insulin-induced gene", Nat Commun, 10, pp.623~ (2019)
- Hardie DG, "Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase", Biochem Soc Trans, 30, pp.1064~1070 (2002)
- Hay N, "Reprogramming glucose metabolism in cancer: Can it be exploited for cancer therapy?", Nat Rev Cancer, 16, pp.635~649 (2016)
- Jones RG, "AMPactivated protein kinase induces a p53-dependent metabolic checkpoint", Mol Cell, 18, pp.283~293 (2005)
- 김정목, "AMPK activators: mechanisms of action and physiological activities", Experimental and Molecular Medicine, 48, pp.1~12 (2016), 생화학분자생물학회
- Kim YD, "Metformin inhibits hepatic gluconeogenesis through AMPactivated protein kinase-dependent regulation of the orphan nuclear receptor SHP", Diabetes, 57, pp.306~314 (2008)
- Eunjeong Ko, "Antitumor Activity of Combination Therapy with Metformin and Trametinib in Non-Small Cell Lung Cancer Cells", 발생과 생식, 24(2), pp.113~123 (2020), 한국발생생물학회
- Krishnan UA, "AMPK activation by AICAR reduces diet induced fatty liver in C57BL", 6 mice, 2023, pp.82, 102054~
- 이재련, "Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells", 발생과 생식, 21(2), pp.139~150 (2017), 한국발생생물학회
- Liu W, "Hepatic P38 activation modulates systemic metabolism through Fgf21-mediated interorgan communication", Diabetes, 71, pp.60~72 (2022)
- Ma X, "NOD2inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway", Cell Death Dis, 11, pp.174~ (2020)
- Mosmann T, "Rapid colorimetric assay for cellular growth and survival: Application application to proliferation and cytotoxicity assays", J Immunol Methods, 65, pp.55~63 (1983)
- 박덕배, "Metformin Promotes Apoptosis but Suppresses Autophagy in Glucose-Deprived H4IIE Hepatocellular Carcinoma Cells", Diabetes and Metabolism Journal, 39(6), pp.518~527 (2015), 대한당뇨병학회[DOI]
- Park D, "Metformin induces oxidative stress-mediated apoptosis without the blockade of glycolysis in H4IIE hepatocellular carcinoma cells", Biol Pharm Bull, 42, pp.2002~2008 (2019)
- Raez LE, "A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors", Cancer Chemother Pharmacol, 71, pp.523~530 (2013)
- Rena G, "The mechanisms of action of metformin", Diabetologia, 60, pp.1577~1585 (2017)
- Rudalska R, "LXRαactivation and Raf inhibition trigger lethal lipotoxicity in liver cancer", Nat Cancer, 2, pp.201~217 (2021)
- Schuster S, "FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells", Biochem Biophys Res Commun, 458, pp.334~340 (2015)
- Stumvoll M, "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus", N Engl J Med, 333, pp.550~554 (1995)
- Sun L, "Elevated expression of RIT1 hyperactivates RAS", MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor, 2022, pp.41, 732~744
- Vaupel P, "The Warburg effect: Essential part of metabolic reprogramming and central contributor to cancer progression", Int J Radiat Biol, 95, pp.912~919 (2019)
- Viollet B, "Revisiting the mechanisms of metformin action in the liver", Ann Endocrinol (Paris), 74, pp.123~129 (2013)
- Wang L, "Inhibition of USP1 activates ER stress through Ubi-protein aggregation to induce autophagy and apoptosis in HCC", Cell Death Dis, 13, pp.951~ (2022)
- Ward PS, "Metabolic reprogramming: A cancer hallmark even warburg did not anticipate", Cancer Cell, 21, pp.297~308 (2012)
- Yang W, "Cimifugin ameliorates lipotoxicity-induced hepatocyte damage and steatosis through TLR4", p38 MAPKand SIRT1-involved pathways, 2022, pp.2022, 4557532~
- Yin J, "Effects of berberine on glucose metabolism in vitro", Metabolism, 51, pp.1439~1443 (2002)
- Yong HY, "The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer", Expert Opin Investig Drugs, 18, pp.1893~1905 (2009)
- Zhang H, "Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: A meta-analysis", Scand J Gastroenterol, 48, pp.78~87 (2013)
- Zhang P, "Association of metformin use with cancer incidence and mortality: A meta-analysis", Cancer Epidemiol, 37, pp.207~218 (2013)
- Zhang Y, "Metformin actions on the liver: Protection mechanisms emerging in hepatocytes and immune cells against NASH-related HCC", Int J Mol Sci, 22, pp.5016~ (2021)